These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22582973)

  • 1. Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds.
    Nevin DK; Peters MB; Carta G; Fayne D; Lloyd DG
    J Med Chem; 2012 Jun; 55(11):4978-89. PubMed ID: 22582973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands.
    Seimandi M; Lemaire G; Pillon A; Perrin A; Carlavan I; Voegel JJ; Vignon F; Nicolas JC; Balaguer P
    Anal Biochem; 2005 Sep; 344(1):8-15. PubMed ID: 16038868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rapid, homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARalpha/gamma activator.
    Seethala R; Golla R; Ma Z; Zhang H; O'Malley K; Lippy J; Cheng L; Mookhtiar K; Farrelly D; Zhang L; Hariharan N; Cheng PT
    Anal Biochem; 2007 Apr; 363(2):263-74. PubMed ID: 17335769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPARs as therapeutic targets in cardiovascular disease.
    van Bilsen M; van Nieuwenhoven FA
    Expert Opin Ther Targets; 2010 Oct; 14(10):1029-45. PubMed ID: 20854178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
    Aleshin S; Grabeklis S; Hanck T; Sergeeva M; Reiser G
    Mol Pharmacol; 2009 Aug; 76(2):414-24. PubMed ID: 19483106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
    Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
    ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype.
    Kuwabara N; Oyama T; Tomioka D; Ohashi M; Yanagisawa J; Shimizu T; Miyachi H
    J Med Chem; 2012 Jan; 55(2):893-902. PubMed ID: 22185225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The peroxisome proliferator-activated receptor N-terminal domain controls isotype-selective gene expression and adipogenesis.
    Hummasti S; Tontonoz P
    Mol Endocrinol; 2006 Jun; 20(6):1261-75. PubMed ID: 16556736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding.
    Batista FA; Trivella DB; Bernardes A; Gratieri J; Oliveira PS; Figueira AC; Webb P; Polikarpov I
    PLoS One; 2012; 7(5):e33643. PubMed ID: 22606221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bidirectional fluorescence properties of pyrene-based peroxisome proliferator-activated receptor (PPAR) α/δ dual agonist.
    Ban S; Oyama T; Kasuga J; Ohgane K; Nishio Y; Morikawa K; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2012 Jun; 20(11):3460-4. PubMed ID: 22551628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.
    Makadia P; Shah SR; Pingali H; Zaware P; Patel D; Pola S; Thube B; Priyadarshini P; Suthar D; Shah M; Giri S; Trivedi C; Jain M; Patel P; Bahekar R
    Bioorg Med Chem; 2011 Jan; 19(2):771-82. PubMed ID: 21215640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity landscape modeling of PPAR ligands with dual-activity difference maps.
    Méndez-Lucio O; Pérez-Villanueva J; Castillo R; Medina-Franco JL
    Bioorg Med Chem; 2012 Jun; 20(11):3523-32. PubMed ID: 22564380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptor alpha, delta, gamma1 and gamma2 expressions are present in human monocyte-derived dendritic cells and modulate dendritic cell maturation by addition of subtype-specific ligands.
    Jakobsen MA; Petersen RK; Kristiansen K; Lange M; Lillevang ST
    Scand J Immunol; 2006 May; 63(5):330-7. PubMed ID: 16640656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
    Moulin D; Bianchi A; Boyault S; Sebillaud S; Koufany M; Francois M; Netter P; Jouzeau JY; Terlain B
    Arthritis Rheum; 2005 Mar; 52(3):759-69. PubMed ID: 15751073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand- and structure-based drug design strategies and PPARδ/α selectivity.
    Maltarollo VG; Honório KM
    Chem Biol Drug Des; 2012 Oct; 80(4):533-44. PubMed ID: 22672760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
    Shioi R; Okazaki S; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3131-3134. PubMed ID: 28539218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Design, synthesis, and PPARalpha/gamma agonistic activity of novel tetrahydroisoquinoline derivatives].
    Yu R; Zhou YL; Huan Y; Liu Q; Shen ZF; Liu ZZ
    Yao Xue Xue Bao; 2011 Mar; 46(3):311-6. PubMed ID: 21626786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phospholipase A2-modified low-density lipoprotein activates macrophage peroxisome proliferator-activated receptors.
    Namgaladze D; Morbitzer D; von Knethen A; Brüne B
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):313-20. PubMed ID: 19948841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A stereo-controlled synthesis of 2,4-dimethyl-4-hydroxy-16-phenylhexadecanoic acid 1,4-lactone and its PPAR activities.
    Ko J; Hwang H; Chin J; Hahn D; Lee J; Yang I; Shin K; Ham J; Kang H
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6017-9. PubMed ID: 20822906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.